Alzinova Team

Chief Executive Officer since 2019

Kristina has 30 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.

Shareholdings and warrants:
50 000 shares
Warrants granting acquisition rights to:
53 000 shares (2020/2023, incentive program)

Education: MSc Pharmacy, PhD in Clinical Pharmacology

Other assignments: Board member of GU Ventures

Chief Scientific Officer since 2015

Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on protein stability and folding. Anders has since 2007 worked with neurotoxic peptide aggregates, which led to the development of ALZ-101 and ALZ-201. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.

Shareholdings and warrants:
167 693 shares
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)

Education: PhD in Chemistry

Other assignments: –

Chief Financial Officer since 2020

Håkan has more than 25 years of experience from leading finance positions in the shipping industry. He has previously worked as CFO and CEO at a privately owned Swedish shipping company with international operations where he has been involved in building the company. Håkan worked as CFO for Safe at Sea AB. Håkan also works as financial consultant for small and medium-sized companies.

Shareholdings and warrants:
34 000 shares
Warrants granting acquisition rights to:
21 000 shares (2020/2023, incentive program)

Education: BSc Business and Economics, Small business management

Other assignments: –

Intellectual Property Officer since 2021

Ann-Sofie Sternås has more than 25 years of experience in IP/patent matters from the pharmaceutical industry. She has an in-depth understanding and knowledge of IP strategic matters, with a heavy focus on the US legislation, particularly IP matters in the interface between patent legislation and regulatory law. Ann-Sofie has previously worked at AstraZeneca and Pharmacia on IP-related matters from a global perspective, including more than 10 years in the IP litigation of several blockbuster drugs. She has also worked at the investment company Karolinska Development AB.

Shareholdings and warrants: –

Education: Authorized European Patent Attorney; Authorized Swedish Patent Attorney. M. Sc. Chemistry education from Royal Institute of Technology

Other assignments: Head of IP in several Swedish pharma/biotech companies.

Business Development Director since 2023

Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.

Shareholdings and warrants:
Shares: 24 000

Education: MSc in Chemistry, PhD in Molecular Biophysics, MBA, Certified Board Member.

Other assignments: Board member of Bulb Intelligence AB, Tyto Competitive Intelligence Solutions AB and Scientific Intelligence Consulting Öresund AB.

Development Project Director since 2021

Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond. Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies.

Shareholdings and warrants:
7 925 shares

Education: MSc Chemical Engineering, PhD Molecular Biology

Other assignments: CEO, ESP Life Science Consulting AB.

Clinical Development Director since 2022

Sandra has more than 25 years of experience of strategic and operational global drug development from pharmaceutical and biotech companies. She worked at AstraZeneca in global clinical development and cross-functional project management positions predominately in the neuroscience area. She also works as a senior pharmaceutical clinical development consultant supporting small and medium sized biotech and drug development companies in different operational and leadership roles in all phases of clinical development. Prior to joining the industry, she worked as a Registered Nurse in the UK’s NHS.

Shareholdings and warrants: –

Education: MSc in Health Sciences

Other assignments: Owner and Senior Pharmaceutical Clinical Development Consultant for Bevan Consulting AB.

Head of Regulatory Affairs since 2022

Margareth Jorvid has over 30 years of experience in Regulatory Affairs and has worked at the Swedish Medical Products Agency (MPA) as well as in local and global roles for large and small pharmaceutical companies, such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and QA for pharmaceuticals, advanced therapies and medical devices through her company Methra Uppsala AB, LSM group. She is a member and honorary member of TOPRA (Organisation for Professionals in Regulatory Affairs), TOPRA Board member 2004-2012 and TOPRA President 2005-2006.

Shareholdings and warrants:
9 000 shares

Education: MSc Pharmacy, MSc Medical Technology Regulatory Affairs (MTRA) and MBA

Other assignments: Owner and CEO of Methra Uppsala AB. Board member of Elicera Therapeutics AB.

Executive Assistant & Communications since 2020

Cecilia has over 10 years of experience in the biopharma industry and more than 20 years in administration.

Shareholdings and warrants: –